EU advises against AstraZeneca shot in people with rare blood condition By Reuters

© Reuters. FILE PHOTO: A vial of AstraZeneca coronavirus vaccine is seen at a vaccination centre in Westfield Stratford City shopping centre, amid the outbreak of coronavirus disease (COVID-19), in London, Britain, February 18, 2021. REUTERS/Henry Nicholls/File Phot

(Reuters) – Europe’s drug regulator on Friday advised against using AstraZeneca (NASDAQ:)’s COVID-19 vaccine in people with a history of a rare bleeding condition and said it was looking into heart inflammation cases after inoculation with all coronavirus shots.

The European Medicines Agency’s (EMA) safety committee in its evaluation said that capillary leak syndrome must be added as a new side effect to labelling on AstraZeneca’s vaccine.

It is a condition in which blood leaks from the smallest of vessels into muscles and body cavities and is characterised by swelling and a drop in blood pressure.

The regulator first began looking into these cases in April and the recommendation adds to AstraZeneca’s woes after its vaccine has been dogged with problems, including a possible link to rare blood clotting issues.

Last month, the EMA had advised against using the second AstraZeneca shot for people with the clotting conditions.

The watchdog is also broadening its probe into cases of myocarditis and pericarditis following inoculation with AstraZeneca’s vaccine and other shots from Pfizer (NYSE:), Moderna (NASDAQ:) and J&J (NYSE:).

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*